Shifting the lines against central nervous system disorders
  • [Corporate] Home Banner

About Theranexus

Theranexus is a clinical-stage biopharmaceutical company that emerged from the French Alternative Energies and Atomic Energy Commission (CEA) in 2013. It develops drug candidates for the treatment of nervous system diseases. Thanks to its knowledge of neuron and glial cell interactions, THERANEXUS is a pioneer in the design and combination of approved substances and has a solid and diversified portfolio of drug candidates in clinical-phase testing. The company’s combined drug repurposing strategy based on a solid commercial footing and a capability to rapidly demonstrate its clinical worth, enables it to produce different high-value-added proprietary drug candidates, significantly reduce development time and costs, and considerably increase the chance of its drugs reaching the market. Accordingly, THERANEXUS is well-positioned in several indications, including for Parkinson’s and Batten disease, for which there is currently no treatment available. Theranexus is listed on the Euronext Growth market in Paris (FR0013286259- ALTHX).

2020 full-year results and update on the progress of main programs

07/04/2021
Download PDF File (1443Ko)

THERANEXUS extends the capabilities of Neurolead, its active agent screening platform, to autophagy and neurological lysosomal storage disorders

09/03/2021
Download PDF File (326Ko)

THERANEXUS presents an update on the progress of its main programs and announces its cash position as of 31 December 2020

18/01/2021
Download PDF File (538Ko)

THERANEXUS, Lyon Neuroscience Research Center and CERMEP announce the creation and funding of new joint public/private laboratory “Neuroimaging for Drug Discovery” (NI2D)

18/12/2020
Download PDF File (428Ko)

The Food And Drug Administration (FDA) issues a favorable opinion on the preclinical development plan submitted by THERANEXUS and BBDF

19/11/2020
Download PDF File (318Ko)